LKM1 Autoantibodies in Chronic Hepatitis C Infection: a Case of Molecular Mimicry?
Overview
Affiliations
Anti-liver-kidney microsome type 1 (LKM1) autoantibodies directed against the cytochrome P450 2D6 (CYP2D6) are considered specific markers of type 2 autoimmune hepatitis, but are also found in 5% of sera from patients chronically infected by hepatitis C virus (HCV). Molecular mimicry between HCV proteins and CYP2D6 has been proposed to explain the emergence of these autoantibodies. Anti-LKM1 autoantibodies from hepatitis C-infected patients were affinity-purified against immobilized CYP2D6 protein and used to screen a phage display library. CYP2D6 conformational epitopes were identified using phage display analysis and the identification of statistically significant pairs (SSPs). Cross-reactivity between CYP2D6 and HCV protein candidates was tested by immunoprecipitation. Nineteen different clones were isolated, and their sequencing resulted in the mapping of a conformational epitope to the region of amino acids 254-288 of CYP2D6. Candidate HCV proteins for molecular mimicry included: core, E2, NS3 and NS5a. Affinity-purified autoantibodies from HCV+/LKM1+ patients immunoprecipitated either NS3, NS5a, or both, and these reactivities were specifically inhibited by immobilized CYP2D6. In conclusion, HCV+/LKM1+ sera recognize a specific conformational epitope on CYP2D6 between amino acids 254 to 288, the region that contains the major linear epitope in type 2 autoimmune hepatitis patients. Cross-reactivity due to molecular mimicry at the B-cell level was shown between the CYP2D6 and the HCV NS3 and NS5a proteins and could explain the presence of anti-LKM1 in patients chronically infected with HCV. Further investigation of the role played by this molecular mimicry in HCV-infected patients may lead to more specific strategies for diagnosis and treatment.
Molecular mimicry and autoimmunity in the time of COVID-19.
Rojas M, Herran M, Ramirez-Santana C, Leung P, Anaya J, Ridgway W J Autoimmun. 2023; 139:103070.
PMID: 37390745 PMC: 10258587. DOI: 10.1016/j.jaut.2023.103070.
Type 2 autoimmune hepatitis: Genetic susceptibility.
Lapierre P, Alvarez F Front Immunol. 2022; 13:1025343.
PMID: 36248826 PMC: 9556705. DOI: 10.3389/fimmu.2022.1025343.
High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection.
de Castro G, da Silva Graca Amoras E, Araujo M, Conde S, Bichara C, Queiroz M Eur J Med Res. 2022; 27(1):180.
PMID: 36114565 PMC: 9479388. DOI: 10.1186/s40001-022-00809-6.
The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.
Liwinski T, Heinemann M, Schramm C Semin Immunopathol. 2022; 44(4):485-507.
PMID: 35536431 PMC: 9088151. DOI: 10.1007/s00281-022-00936-6.
Pathogens and autoimmune hepatitis.
Christen U, Hintermann E Clin Exp Immunol. 2018; 195(1):35-51.
PMID: 30113082 PMC: 6300650. DOI: 10.1111/cei.13203.